Pembrolizumab’s Perioperative Power in Head and Neck Cancer
Adding pembrolizumab before and after surgery to standard of care improved outcomes in patients with previously untreated head and neck cancer.
Progress Against Cancer
Adding pembrolizumab before and after surgery to standard of care improved outcomes in patients with previously untreated head and neck cancer.
A recently approved first-line therapy and novel insights into optimizing treatment strategies may offer new options for esophageal cancer patients.
The test, which analyzes urine for 18 cancer-specific genes, ruled out the need for biopsy in men with elevated PSA without a digital rectal exam.
Saliva test can help identify people who are at high risk of recurrence after mouth or throat cancer treatment.
Researchers analyze whether giving immunotherapy before surgery benefits people with high-risk disease that is limited to the liver.
Patients who received Opdivo and chemotherapy had better outcomes and fewer side effects than those who had the standard-of-care therapy.
An experimental antibody helped people recover body mass lost due to cancer and treatment.
Shorter, more intense radiation regimens may be as effective as traditional treatments, with greater convenience for patients.
People with metastatic hormone receptor-positive breast cancer are living longer, thanks to new targeted therapies and endocrine therapies that can be prescribed when treatment resistance develops.
Blood tests can guide treatment choices, delivering results in less time than traditional biopsies.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More